[1]范玲玲,王成海.浆液性卵巢癌SFRP2和MORC2的表达及其预后意义[J].医学信息,2026,39(05):16-21.[doi:10.3969/j.issn.1006-1959.2026.05.003]
 FAN Lingling,WANG Chenghai.Expression of SFRP2 and MORC2 in Serous Ovarian Cancer and its Prognostic Significance[J].Journal of Medical Information,2026,39(05):16-21.[doi:10.3969/j.issn.1006-1959.2026.05.003]
点击复制

浆液性卵巢癌SFRP2和MORC2的表达及其预后意义()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年05期
页码:
16-21
栏目:
生物信息学
出版日期:
2026-03-01

文章信息/Info

Title:
Expression of SFRP2 and MORC2 in Serous Ovarian Cancer and its Prognostic Significance
文章编号:
1006-1959(2026)05-0016-06
作者:
范玲玲12王成海1
1.扬州大学医学院病理学教研室,江苏 扬州 225009;2.海门区人民医院妇产科,江苏 南通 226100
Author(s):
FAN Lingling12 WANG Chenghai1
1.Department of Pathology, Medical College, Yangzhou University, Yangzhou 225009, Jiangsu, China;2.Department of Obstetrics and Gynecology, Haimen District People′s Hospital, Nantong 226100, Jiangsu, China
关键词:
浆液性卵巢癌SFRP2MORC2病理意义生存预后
Keywords:
Serous ovarian cancer SFRP2 MORC2 Pathological significance Survival prognosis
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2026.05.003
文献标志码:
A
摘要:
目的 观察SFRP2和MORC2在浆液性卵巢癌组织中的表达,并分析其与临床病理意义和预后的相关性。方法 收集2019年-2021年58对浆液性卵巢癌和癌旁正常组织及病理资料。在浆液性卵巢癌和癌旁正常组织中运用免疫组织化学(IHC)方法检测SFRP2和MORC2的蛋白表达情况。统计分析SFRP2和MORC2的表达与患者临床病理参数和生存预后之间的关系。结果 HE染色显示浆液性卵巢癌特点:浆液性卵巢癌形成乳头状,低级别浆液性癌可见癌细胞异型性小,核分裂少;高级别浆液性癌,癌细胞异型明显,常见瘤巨细胞,病理性核分裂多见。IHC结果显示,在浆液性卵巢癌和癌旁正常组织中SFRP2、MORC2阳性表达率比较,差异有统计学意义(P<0.05);在浆液性卵巢癌不同的FIGO分期中SFRP2和MORC2表达比较,差异有统计学意义(P<0.05);而在年龄、病理分级和淋巴结转移中SFRP2和MORC2表达比较,差异无统计学意义(P>0.05);SFRP2和MORC2两者表达水平越高,患者生存时间越短。结论 在浆液性卵巢癌中SFRP2和MORC2表达水平均增高,SFRP2和MORC2表达可能与浆液性卵巢癌的FIGO分期和不良预后相关。
Abstract:
Objective To observe the expression of SFRP2 and MORC2 in serous ovarian cancer tissues, and analyze their correlation with clinicopathological significance and prognosis. Methods The pathological data of 58 pairs of serous ovarian cancer and adjacent normal tissues from 2019 to 2021 were collected. Immunohistochemistry (IHC) was used to detect the protein expression of SFRP2 and MORC2 in serous ovarian cancer and adjacent normal tissues. The relationship between the expression of SFRP2, MORC2 and the clinicopathological parameters, survival prognosis of patients was statistically analyzed. Results HE staining showed the characteristics of SOC: serous ovarian cancer formed a papillary shape, low-grade serous cancer showed small cancer cell atypia and few nuclear division; high-grade serous carcinoma with obvious cancer cell atypia, tumor giant cells and pathological mitosis were common. The IHC results showed that the positive expression rates of SFRP2 and MORC2 were significantly different between serous ovarian cancer and adjacent normal tissues (P<0.05). There were significant differences in the expression of SFRP2 and MORC2 in different FIGO stages of serous ovarian cancer (P<0.05). There were no significant differences in age, pathological grade and lymph node metastasis (P>0.05). The higher the expression level of SFRP2 and MORC2, the shorter the survival time of patients. Conclusion The expression levels of SFRP2 and MORC2 are increased in serous ovarian cancer, and the expression of SFRP2 and MORC2 may be related to FIGO stage and poor prognosis of serous ovarian cancer.

参考文献/References:

[1]Siegel RL,Miller KD,et al.Cancer statistics, 2023[J].CA Cancer J Clin,2023,73(1):17-48.[2]Hu Y,Fu K,Liu H,et al.Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?[J].J Ovarian Res,2023,16(1):18.[3]Zhang Y,Sun S,Qi Y,et al.Characterization of tumour microenvironment reprogramming reveals invasion in epithelial ovarian carcinoma[J].J Ovarian Res,2023,16(1):200.[4]Kolb S,Hoffmann I,Monjé N,et al.LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma[J].Hum Pathol,2023,141:158-168.[5]Gyorffy B.Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer[J].Geroscience,2023,45(3):1889-1898.[6]Jung YS,Park JI.Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex[J].Exp Mol Med,2020,52(2):183-191.[7]Kaur A,Webster MR,Marchbank K,et al.sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance[J].Nature,2016,532(7598):250-254.[8]Akova ?魻lken E,Aszodi A,Taipaleenm?覿ki H,et al.SFRP2 Overexpression Induces an Osteoblast-like Phenotype in Prostate Cancer Cells[J].Cells,2022,11(24):4081.[9]Byun HJ,Yoon JH,Lee SK.LUCAT1 Epigenetically Downregulates the Tumor Suppressor Genes CXXC4 and SFRP2 in Gastric Cancer[J].Yonsei Med J,2020,61(11):923-934.[10]Zhang Q,Song Y,Chen W,et al.By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer[J].Oncotarget,2015,6(18):16461-16470.[11]Zhang S,Guo A,Wang H,et al.Oncogenic MORC2 in cancer development and beyond[J].Genes Dis,2023,11(2):861-873.[12]Tan Y,Zheng T,Su Z,et al.Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis[J].JCI Insight,2023,8(18):e162893.[13]Lheureux S,Gourley C,Vergote I,et al.Epithelial ovarian cancer[J].Lancet,2019,393(10177):1240-1253.[14]Zheng W.Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists[J].Cancers (Basel),2023,15(16):4101.[15]Akova ?魻lken E,Aszodi A,Taipaleenm?覿ki H,et al.SFRP2 Overexpression Induces an Osteoblast-like Phenotype in Prostate Cancer Cells[J].Cells,2022,11(24):4081.[16]Xiao X,Xiao Y,Wen R,et al.Promoting roles of the secreted frizzled-related protein 2 as a Wnt agonist in lung cancer cells[J].Oncol Rep,2015,34(5):2259-2266.[17]Roth W,Wild-Bode C,Platten M,et al.Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells[J].Oncogene,2000,19(37):4210-4220.[18]Wang H,Zhang L,Luo Q,et al.MORC protein family-related signature within human disease and cancer[J].Cell Death Dis,2021,12(12):1112.[19]Ding QS,Zhang L,Wang BC,et al.Aberrant high expression level of MORC2 is a common character in multiple cancers[J].Hum Pathol,2018,76:58-67.[20]Zhang S,Guo A,Wang H,et al.Oncogenic MORC2 in cancer development and beyond[J].Genes Dis,2023,11(2):861-873.[21]Mohapatra B,Pakala SB.Emerging roles of the chromatin remodeler MORC2 in cancer metabolism[J].Med Oncol,2024,41(9):221.

相似文献/References:

[1]李 朝,周玉明,姜 茹,等.嘌呤能受体在卵巢癌中的预后价值及肿瘤免疫浸润分析[J].医学信息,2024,37(17):1.[doi:10.3969/j.issn.1006-1959.2024.17.001]
 LI Zhao,ZHOU Yu-ming,JIANG Ru,et al.Prognostic Value of Purinergic Receptors in Ovarian Cancer and Analysis of Tumor Immune Infiltration[J].Journal of Medical Information,2024,37(05):1.[doi:10.3969/j.issn.1006-1959.2024.17.001]

更新日期/Last Update: 1900-01-01